Venkat Subramaniam
Metairie, LANPI 1437681186
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.5%), travel and lodging and education — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Edwards Lifesciences at 25.8% of the total.
Across 150 payments — averaging $53.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$2K
- Boston Scientific$2K
- Medtronic$2K
- Abiomed$918
- Abbott$515
- Amgen$319
- plus $1K from 14 others
What the payments were for
- Travel & lodging$2,81935%
- Food & beverage$4,73860%
- Education$4005%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 19 | $2,053 |
| Boston Scientific | 16 | $1,590 |
| Medtronic | 20 | $1,558 |
| Abiomed | 23 | $918 |
| Abbott | 19 | $515 |
| Amgen | 15 | $319 |
| Penumbra, Inc. | 1 | $143 |
| Biotronik Inc. | 3 | $141 |
| Novo Nordisk | 6 | $141 |
| E.r. Squibb & Sons, L.L.C. | 7 | $134 |
| Johnson & Johnson | 6 | $110 |
| Shockwave Medical, Inc | 3 | $77 |
| Pfizer | 4 | $71 |
| Boehringer Ingelheim | 2 | $40 |
| Stryker | 1 | $31 |
| AstraZeneca | 1 | $30 |
| Lexicon Pharmaceuticals, Inc. | 1 | $28 |
| Livanova USA, Inc. | 1 | $22 |
| Merck | 1 | $19 |
| Janssen Scientific Affairs, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PASCAL$1,087
- ACCOLADE SR$1,033
- COREVALVE EVOLUT R$785
- ONYX FRONTIER$399
- SAPIEN 3 Ultra RESILIA$190
- Indigo System$143
- MitraClip$117
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 43 | $28,917 |
| EntrestoSacubitril/Valsartan | 24 | $24,856 |
| JardianceEmpagliflozin | 13 | $21,678 |
| Nifedipine ErNifedipine | 24 | $502 |
| Metoprolol Succinate | 32 | $442 |
| Atorvastatin Calcium | 43 | $387 |
| Nitroglycerin | 20 | $296 |
| Amlodipine Besylate | 23 | $164 |
| ClopidogrelClopidogrel Bisulfate | 23 | $161 |
| Carvedilol | 21 | $159 |
| Spironolactone | 12 | $142 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 19 | $113 |
| Furosemide | 19 | $75 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $71 | $28,91743 claims |
| Boehringer IngelheimJardiance | $40 | $21,67813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Louisianaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.